Development of an Optimized Adjuvanted TB Vaccine
$358,674N01FY2024AINIH
University Of Montana, Missoula MT
Investigators
Abstract
To identify the optimal adjuvant for recombinant vaccines and inactivated flu vaccines, and to identify correlates of protection against infection or disease, experimental vaccines will be formulated with a panel of different vaccine adjuvants and tested side-by-side for immunogenicity and efficacy.
View original record on NIH RePORTER →